Derek Mendy

2.2k total citations · 1 hit paper
21 papers, 1.3k citations indexed

About

Derek Mendy is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, Derek Mendy has authored 21 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Molecular Biology, 16 papers in Hematology and 5 papers in Oncology. Recurrent topics in Derek Mendy's work include Multiple Myeloma Research and Treatments (16 papers), Protein Degradation and Inhibitors (15 papers) and Ubiquitin and proteasome pathways (9 papers). Derek Mendy is often cited by papers focused on Multiple Myeloma Research and Treatments (16 papers), Protein Degradation and Inhibitors (15 papers) and Ubiquitin and proteasome pathways (9 papers). Derek Mendy collaborates with scholars based in United States, Switzerland and Japan. Derek Mendy's co-authors include Antonia Lopez‐Girona, Peter Schäfer, Anita K. Gandhi, Rajesh Chopra, Svetlana Gaidarova, Tom Daniel, Brian E. Cathers, Emily Rychak, Mahan Abbasian and Pilgrim J. Jackson and has published in prestigious journals such as Blood, eLife and British Journal of Haematology.

In The Last Decade

Derek Mendy

21 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide

2012 606 citations Antonia Lopez‐Girona, Derek Mendy et al. Leukemia profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Derek Mendy United States	10	1.1k	771	518	131	129	21	1.3k
Slater N. Hurst United States	6	1.3k 1.1×	672 0.9×	440 0.8×	72 0.5×	157 1.2×	9	1.5k
Jessica Schmidt United States	14	1.4k 1.2×	1.0k 1.3×	477 0.9×	132 1.0×	95 0.7×	22	1.6k
Huahang Sun United States	2	1.0k 0.9×	523 0.7×	335 0.6×	64 0.5×	104 0.8×	2	1.1k
Emily Rychak Japan	6	969 0.9×	669 0.9×	381 0.7×	87 0.7×	85 0.7×	10	1.1k
K. Martin Kortuem United States	10	667 0.6×	557 0.7×	276 0.5×	53 0.4×	65 0.5×	20	853
Bangzheng Chen United States	6	584 0.5×	430 0.6×	320 0.6×	114 0.9×	155 1.2×	8	900
Mahan Abbasian United States	9	637 0.6×	431 0.6×	281 0.5×	78 0.6×	132 1.0×	13	830
Yan Ren China	12	841 0.8×	588 0.8×	338 0.7×	56 0.4×	114 0.9×	30	1.0k
Manuela Mancini Italy	21	483 0.4×	500 0.6×	180 0.3×	95 0.7×	92 0.7×	60	1.1k
Julia Etchin United States	11	1.2k 1.0×	232 0.3×	297 0.6×	72 0.5×	89 0.7×	18	1.4k

Countries citing papers authored by Derek Mendy

Since Specialization

Citations

This map shows the geographic impact of Derek Mendy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Derek Mendy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Derek Mendy more than expected).

Fields of papers citing papers by Derek Mendy

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Derek Mendy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Derek Mendy. The network helps show where Derek Mendy may publish in the future.

Co-authorship network of co-authors of Derek Mendy

This figure shows the co-authorship network connecting the top 25 collaborators of Derek Mendy. A scholar is included among the top collaborators of Derek Mendy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Derek Mendy. Derek Mendy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mo, Zhongying, Lynda Groocock, Scott Wood, et al.. (2022). Elucidating the Molecular Mechanisms of Action of CC-99282, a Novel Cereblon (CRBN) E3 Ligase Modulator (CELMoD) Agent, Via Genome-Wide CRISPR Screen in a Preclinical Model of Non-Hodgkin Lymphoma (NHL). Blood. 140(Supplement 1). 8860–8861. 2 indexed citations

Lopez‐Girona, Antonia, Lynda Groocock, Zhongying Mo, et al.. (2021). CC‐99282 IS A NOVEL CEREBLON E3 LIGASE MODULATOR (CELMOD) AGENT WITH POTENT AND BROAD ANTITUMOR ACTIVITY IN PRECLINICAL MODELS OF DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL). Hematological Oncology. 39(S2). 4 indexed citations

Lopez‐Girona, Antonia, Gang Lu, Emily Rychak, et al.. (2019). CC-90009, a Novel Cereblon E3 Ligase Modulator, Targets GSPT1 for Degradation to Induce Potent Tumoricidal Activity Against Acute Myeloid Leukemia (AML). Blood. 134(Supplement_1). 2703–2703. 16 indexed citations

Lopez‐Girona, Antonia, Courtney G. Havens, Gang Lu, et al.. (2019). CC-92480 Is a Novel Cereblon E3 Ligase Modulator with Enhanced Tumoricidal and Immunomodulatory Activity Against Sensitive and Resistant Multiple Myeloma Cells. Blood. 134(Supplement_1). 1812–1812. 18 indexed citations

Rychak, Emily, Derek Mendy, Tao Shi, et al.. (2016). Pomalidomide in combination with dexamethasone results in synergistic anti‐tumour responses in pre‐clinical models of lenalidomide‐resistant multiple myeloma. British Journal of Haematology. 172(6). 889–901. 40 indexed citations

Gandhi, Anita K., Derek Mendy, Michelle F. Waldman, et al.. (2013). Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity. British Journal of Haematology. 164(2). 233–244. 71 indexed citations

Rychak, Emily, Derek Mendy, Karen Miller, et al.. (2013). The Novel mTOR Kinase Inhibitor CC-223 Demonstrates Significant Activity In In Vitro Models Of Multiple Myeloma (MM), Both As a Single Agent and In Combination With The Approved Agents, Dexamethasone, Lenalidomide and Pomalidomide. Blood. 122(21). 3160–3160. 1 indexed citations

Thakurta, Anjan, Anita K. Gandhi, Michelle F. Waldman, et al.. (2013). Absence Of Mutation In Cereblon (CRBN) and DNA Damage Binding Protein 1 (DDB1) Genes In Myeloma Cells and Patients and Its Clinical Significance. Blood. 122(21). 3139–3139. 3 indexed citations

Lopez‐Girona, Antonia, Derek Mendy, Takumi Ito, et al.. (2012). Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia. 26(11). 2326–2335. 606 indexed citations breakdown →

10.

Gandhi, Anita K., Hervé Avet‐Loiseau, Michelle F. Waldman, et al.. (2012). Detection and Quantification of Cereblon Protein and mRNA in Multiple Myeloma Cell Lines and Primary CD138+multiple Myeloma Cells. Blood. 120(21). 4043–4043. 1 indexed citations

11.

Schäfer, Peter, Emily Rychak, Derek Mendy, et al.. (2012). Targeting Cereblon with the High Affinity Immunomodulatory Compound CC-220: A Novel Therapeutic Agent for B Cell Dyscrasias. Blood. 120(21). 1055–1055. 1 indexed citations

12.

Gandhi, Anita K., Derek Mendy, Anastasia Parton, et al.. (2012). CC-122 Is a Novel Pleiotropic Pathway Modifier with Potent in Vitro Immunomodulatory and Anti-Angiogenic Properties and in Vivo Anti-Tumor Activity in Hematological Cancers.. Blood. 120(21). 2963–2963. 8 indexed citations

13.

Lopez‐Girona, Antonia, Daniel Heintel, Derek Mendy, et al.. (2011). Lenalidomide downregulates the cell survival factor, interferon regulatory factor‐4, providing a potential mechanistic link for predicting response. British Journal of Haematology. 154(3). 325–336. 137 indexed citations

14.

Lopez‐Girona, Antonia, Derek Mendy, Karen Miller, et al.. (2011). Direct Binding with Cereblon Mediates the Antiproliferative and Immunomodulatory Action of Lenalidomide and Pomalidomide. Blood. 118(21). 738–738. 4 indexed citations

15.

Gandhi, Anita K., Lori Capone, Anastasia Parton, et al.. (2010). Dexamethasone Synergizes with Lenalidomide to Inhibit Multiple Myeloma Tumor Growth, But Reduces Lenalidomide-Induced Immunomodulation of T and NK Cell Function. Current Cancer Drug Targets. 10(2). 155–167. 142 indexed citations

16.

Gaidarova, Svetlana, Derek Mendy, Carla Heise, et al.. (2010). Lenalidomide Induces Capping of CD20 and Cytoskeleton Proteins to Enhance Rituximab Immune Recognition of Malignant B-Cells. Blood. 116(21). 2845–2845. 9 indexed citations

17.

Lopez‐Girona, Antonia, Derek Mendy, Svetlana Gaidarova, & Helen Brady. (2009). B309 Lenalidomide Inhibits the Multiple Myeloma Cell Survival Factor IRF4/MUM1. Clinical Lymphoma & Myeloma. 9. S122–S122. 5 indexed citations

18.

Lopez‐Girona, Antonia & Derek Mendy. (2009). B311 Lenalidomide Treatment Interferes with Ras/MAPK Activation and Induces Apoptosis in Multiple Myeloma. Clinical Lymphoma & Myeloma. 9. S123–S123. 1 indexed citations

19.

Lopez‐Girona, Antonia, et al.. (2008). Stimulation of T Cells by Lenalidomide Involves Putative Lenalidomide Binding Proteins CD3-Epsilon-Associated Protein and GDP-Mannose Pyrophosphorylase a. Blood. 112(11). 2606–2606. 3 indexed citations

20.

Chen, Qing, Weilin Xie, Deborah J. Kuhn, et al.. (2008). Targeting the p27 E3 ligase SCFSkp2 results in p27- and Skp2-mediated cell-cycle arrest and activation of autophagy. Blood. 111(9). 4690–4699. 220 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact